Breast Cancer: Cell and Gene Therapy

References

• Harris J R, Morrow M, Bonadonng, . Cancer of the breast in Cancer: Principles and Practice of Oncology, 4th ed, V Devita, S Hellman, S A Rosenberg, et al. JB Lippincott, Philadelphia 1993; 1264–1332
   Google Scholar
• Vaughan W P. Autologous bone marrow transplantation in the treatment of breast cancer: Clinical and technologic strategies. Semin Oncol 1993; 20(5)55–58
   PubMed Web of Science ®Google Scholar
• Fields K K, Elfenbein G J, Perkins J B, et al. Two novel high-dose treatment regimens for metastatic breast cancer-ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: Outcomes and toxicities. Semin Oncol 1993; 20(5)59–66
   PubMed Web of Science ®Google Scholar
• Jones R B, Shpall E J, Shogan J, et al. Intensive induction chemotherapy for metastatic breast cancer. Cancer 1990; 66: 431–436
   PubMed Web of Science ®Google Scholar
• Bell A J, Hamblin T J, Oscier D G. Peripheral blood stem cell auto-grafting. Hematology 1987; 5: 45–55
   Google Scholar
• Siena S, Bregni M, Brando B, et al. Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: Enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1989; 74(6)1905–1914
   PubMed Web of Science ®Google Scholar
• Socinski M A, Cannistra S A, Elias A, et al. GM-CSF expands the circulating hematopoietic progenitor cell compartment in man. Lancet 1988; 1: 1194–1198
   PubMed Web of Science ®Google Scholar
• Duhrsen U, Villeval J L, Boyd J, et al. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988; 72: 2074–2081
   PubMed Web of Science ®Google Scholar
• Villeval J L, Duhrsen U, Morstyn G, et al. Effects of recombinant human granulocyte-macrophage colony-stimulating factor on progenitor cells in patients with advanced malignancies. Br J Haematol 1990; 74: 36–44
   PubMed Web of Science ®Google Scholar
• Gianni A M, Siena S, Bregni M, et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating hematopoietic stem cells for autotransplantation. Lancet 1989; 2: 580–584
   PubMed Web of Science ®Google Scholar
• Brugger W, Bross K J, Frisch J, et al. Mobilization of peripheral blood progenitor cells by sequential administration of IL-3 and GM-CSF following chemotherapy with etoposide, ifoside, ifosfamide, and cisplatin. Blood 1992; 79: 1193–1200
   PubMed Web of Science ®Google Scholar
• Pettengell R, Demuynck H, Testa N G, et al. The engraftment capacity of peripheral blood progenitor cells mobilized with chemotherapy üü G-CSF. Int J Cell Clon 1992; 10: 59
   Google Scholar
• Elias A D, Ayash L, Anderson K C, et al. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood 1992; 79(11)3036–3044
   PubMed Web of Science ®Google Scholar
• Brugger W, Birken R, Bertz H, et al. Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin. Br J Haematol 1993; 84: 402–407
   PubMed Web of Science ®Google Scholar
• Moss T J, Ross A A. The risk of tumor cell contamination in peripheral blood stem cell collections. J Hematother 1992; 1: 225–232
   PubMedGoogle Scholar
• Ross A A, Cooper B W, Lazarus H M, et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993; 82(9)2605–2610
   PubMed Web of Science ®Google Scholar
• Shpall E J, Jones R B. Release of tumor cells from bone marrow. Blood 1994; 83(3)623–625
   PubMed Web of Science ®Google Scholar
• Brugger W, Bross K J, Glatt M, et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994; 83(3)636–640
   PubMed Web of Science ®Google Scholar
• Rill D R, Santana V M, Roberts W M, et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994; 84(2)380–383
   PubMed Web of Science ®Google Scholar
• Deisseroth A B, Zu Z, Claxton D, et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994; 83(10)3068–3076
   PubMed Web of Science ®Google Scholar
• Shpall E J, Jones R B, Bast R C, et al. 4-Hydroperoxycyclo-phosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: A phase I trial. J Clin Oncol 1991; 9(1)85–93
   PubMedGoogle Scholar
• Shpall E J, Anderson I C, Bast R C, et al. Immunopharmacologic purging of breast cancer from bone marrow for autologous bone marrow transplantation. Bone Marrow Purg Process 1990; 321–336
   Google Scholar
• Shpall E J, Stemmer S M, Johnston C F, et al. Purging of autologous bone marrow for transplantation: The protection and selection of the hematopoietic progenitor cell. J Hematother 1992; 1: 45–54
   PubMedGoogle Scholar
• Berenson R J, Bensinger W I, Hill R S, et al. Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma. Blood 1991; 77(8)1717–1722
   PubMed Web of Science ®Google Scholar
• Shpall E J, Jones R B, Bearman S I, et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose therapy: Influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 1994; 12(1)28–36
   PubMed Web of Science ®Google Scholar
• Brugger W, Henschler R, Heimfeld S, et al. Positively selected autologous blood CD34+ and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin. Blood 1994; 84(5)1421–1426
   PubMed Web of Science ®Google Scholar
• Lebkowski J S, Schain L R, Okrongly D, et al. Rapid isolation of human CD34 hematopoietic stem cells-purging of human tumor cells. Transplantation 1992; 53(5)1011–1019
   PubMed Web of Science ®Google Scholar
• Haylock D N, To L B, Dowse T L, et al. Ex vivo expansion and maturation of peripheral blood CD34+ cells into the myeloid lineage. Blood 1992; 80(6)1405–1412
   PubMed Web of Science ®Google Scholar
• Brugger W, Mocklin W, Heimfeld S, et al. Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1übT (IL-1übT), IL-6, IL-3, interferon-ügM, and erythropoietin. Blood 1993; 81(10)2579–2584
   PubMed Web of Science ®Google Scholar
• Roller M R, Emerson S G, Palsson B O. Large-scale expansion of human stem and progenitor cells from bone marrow mononuclear cells in continuous perfusion cultures. Blood 1993; 82(2)378–384
   PubMed Web of Science ®Google Scholar
• Rummel S A, Van Zant G. Future paradigm for autologous bone marrow transplantation: Tumor purging and ex vivo production of normal stem and progenitor cells. J Hematother 1994; 3: 213–218
   PubMedGoogle Scholar
• Henschler R, Brugger W, Luft T, et al. Maintenance of transplantation potential in ex vivo expanded CD34+ -selected human peripheral blood progenitor cells. Blood 1994; 84(9)2898–2903
   PubMed Web of Science ®Google Scholar
• Lebkowski J S, Schain L, Hall M, et al. Rapid isolation and serum-free expansion of human CD34+ cells. Blood Cells 1994; 20: 404–410
   PubMedGoogle Scholar
• Lebkowski J, Schain L, Harvey M, et al. Direct isolation and expansion of human CD34+ hematopoietic stem cells. J Hematother 1993; 2: 339–342
   PubMedGoogle Scholar
• Shapiro F, Yao T J, Raptis G, et al. Optimization of conditions for ex vivo expansion of CD34+ cells from patients with stage IV breast cancer. Blood 1994; 84(10)3567–3574
   PubMed Web of Science ®Google Scholar
• Cassel A, Cotter-Fox M, Doren S, et al. Retroviral-mediated gene transfer into CD34-enriched human peripheral blood stem cells. Exp Hematol 1993; 21: 585–591
   PubMed Web of Science ®Google Scholar
• Bregni M, Magni M, Siena S, et al. Human peripheral blood hematopoietic progenitors are optimal targets of retroviral-mediated gene transfer. Blood 1992; 80: 1418–1422
   PubMed Web of Science ®Google Scholar
• Moore D E, Deisseroth A B, Reading C L, et al. Stromal support enhanced cell-free retroviral vector transduction of human bone marrow long-term culture-initiating cells. Blood 1992; 79: 1393–1399
   PubMed Web of Science ®Google Scholar
• Lu M, Maruyama M, Zhang N, et al. High efficiency retroviral-mediated gene transduction into CD34+ cells purified from peripheral blood of breast cancer patients primed with chemotherapy and granulocyte-macrophage colony-stimulating factor. Hum Gene Ther 1994; 5: 203–208
   PubMed Web of Science ®Google Scholar
• Von Kalle C, Kiem H P, Goehle S, et al. Increased gene transfer into human hematopoietic progenitor cells by extended in vitro exposure to a pseudotyped retroviral vector. Blood. 1994; 84(9)2890–2897
   PubMed Web of Science ®Google Scholar
• O'Shaughnessy J A, Cowan K H, Wilson W, et al. Pilot study of high dose ICE (ifosfamide, carboplatin, etoposide) chemotherapy and autologous bone marrow transplant (ABMT) with neo R-transduced bone marrow and peripheral blood stem cells in patients with metastic breast cancer. Hum Gene Ther 1993; 4: 331–354
   PubMed Web of Science ®Google Scholar
• Dunbar C E, O'Shaughnessy J A, Cottier-Fox M, et al. Transplantation of retrovirally-marked CD34+ marrow and peripheral blood cells in patients with multiple myeloma or breast cancer. Blood 1993; 82(10)217a, Suppl 1
   PubMed Web of Science ®Google Scholar
• Pastan I, Gottesman M M. Multidrug resistance. Annu Rev Med 1991; 42: 277–286
   PubMed Web of Science ®Google Scholar
• Delaflor-Weiss E, Richardson C, Ward M, et al. Transfer and expansion of the human multidrug resistance gene in mouse erythroleukemia cells. Blood 1992; 80(12)3106–3111
   PubMed Web of Science ®Google Scholar
• Guild B C, Mulligan R C, Gros P, et al. Retroviral transfer of a murine cDNA for multidrug resistance confers pleiotropic drug resistance to cells without prior drug selection. Proc Natl Acad Sci USA 1988; 85: 1595–1599
   PubMed Web of Science ®Google Scholar
• Pastan I, Gottesman M M, Ueda K, et al. A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci USA 1988; 5: 4486–4490
   Google Scholar
• Mickisch G H, Aksentijevich I, Schoenlein P V, et al. Transplantation of bone marrow cells from transgenic mice expressing the human MDR1 gene results in long-term protection against the myelosuppressive effect of chemotherapy in mice. Blood 1992; 79(4)1087–1093
   PubMed Web of Science ®Google Scholar
• Sorrentino B P, Brandt S J, Bodine D, et al. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 1992; 257: 99–103
   PubMed Web of Science ®Google Scholar
• Podda S, Ward M, Himelstein A, et al. Transfer and expression of the human multiple drug resistance gene into live mice. Proc Natl Acad Sci USA 1992; 89: 9676–9680
   PubMed Web of Science ®Google Scholar
• Hanania E G, Fu S, Roninson I, et al. Resistance to taxol chemotherapy produced in mouse marrow cells by safety-modified retroviruses containing a human MDR-1 transcription unit. Gene Ther 1995; 2: 1–6
   Google Scholar
• Ward M, Richardson C, Pioli P, et al. Transfer and expression of the human multiple drug resistance gene in human CD34+ cells. Blood 1994; 84(5)1408–1414
   PubMed Web of Science ®Google Scholar
• Hanania E G, Fu S, Zu Z, et al. Chemotherapy resistance to taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood cells with a retrovirus that contains the MDR-1 chemotherapy resistance gene. Gene Ther 1995; 2: 1–10
   Google Scholar
• Fearon E R, Pardoll D M, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990; 60: 397–403
   PubMed Web of Science ®Google Scholar
• Gansbacher B, Zier K, Daniels B, et al. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990; 172: 1217–1224
   PubMed Web of Science ®Google Scholar
• Gansbacher B, Bannerji R, Daniels B, et al. Retroviral vector-mediated ügM-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 1990; 50: 7820–7825
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Kuribayashi K, Miyatake S, et al. Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells: Results in reduced tumorigenicity by augmented anti-tumor immunity. Proc Natl Acad Sci USA 1989; 86: 9456–9458
   PubMed Web of Science ®Google Scholar
• Restifo N P, Spiess P J, Karp S E, et al. A nonimmunogenic sarcoma transduced with the cDNA for interferon-y elicits CD8+ T cells against wild-type tumor: Correlation with antigen presentation capability. J Exp Med 1992; 175: 1423–1431
   PubMed Web of Science ®Google Scholar
• Golumbek P T, Lazenby A J, Levitzky H I, et al. Treatment of established renal cancer engineered to secrete interleukin-4. Science 1991; 254: 713–716
   PubMed Web of Science ®Google Scholar
• Porgador A, Tzehoval E, Katz A, et al. Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant metastatic cells. Cancer Res 1992; 52: 3679–3686
   PubMed Web of Science ®Google Scholar
• Blankenstein T, Qin Z, Uberla K, et al. Tumor suppression after tumor cell-targeted tumor necrosis factor üü gene transfer. J Exp Med 1991; 173: 1047–1052
   PubMed Web of Science ®Google Scholar
• Ohe Y, Podack E R, Olsen K J, et al. Combination effect of vaccination with IL2 and IL4 cDNA transfected cells on the induction of a therapeutic immune response against Lewis lung carcinoma cells. Int J Cancer 1993; 53: 432–437
   PubMed Web of Science ®Google Scholar
• Porgador A, Gansbacher B, Bannerji R, et al. Anti-metastatic vaccination of tumor-bearing mice with IL-2-gene-inserted tumor cells. Int J Cancer 1993; 53: 471–477
   PubMed Web of Science ®Google Scholar
• Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulated potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539–3543
   PubMed Web of Science ®Google Scholar
• Connor J, Bannerji R, Saito S, et al. Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J Exp Med 1993; 177: 1127–1134
   PubMed Web of Science ®Google Scholar
• Rosenthal F M, Cronin K, Bannerji R, et al. Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-ügM cDNAs. Blood 1994; 83(5)1289–1298
   PubMed Web of Science ®Google Scholar
• Gansbacher B, Rosenthal F M, Zier K. Retroviral vector-mediated cytokine-gene transfer into tumor cells. Cancer Invest 1993; 11(3)345–354
   PubMed Web of Science ®Google Scholar
• Allione A, Consalvo M, Nanni P, et al. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-6, IL-7, IL-10, tumor necrosis factor üü, granulocyte-macrophage colony-stimulating factor, and ügM-interferon gene or admixed with conventional adjuvants. Cancer Res 1994; 54: 6022–6026
   PubMed Web of Science ®Google Scholar
• Rosenberg S A, Anderson W F, Blaese M R, et al. Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for interleukin-2. Hum Gene Ther 1992; 3: 75–90
   PubMedGoogle Scholar
• Taylor-Papadimitriou J, D'Souza B, Burchell J, et al. The role of tumor-associated antigens in the biology and immunotherapy of breast cancer. Ann NY Acad Sci Nov 1993; 30: 31–47
   Google Scholar
• Hareuveni M, Gautier C, Kieny M P, et al. Vaccination against tumor cells expressing breast cancer epithelial tumor antigen. Proc Natl Acad Sci USA 1990; 87: 9498–9502
   PubMed Web of Science ®Google Scholar
• Bu D, Domenech N, Lewis J, et al. Recombinant vaccinia mucin vector: In vitro analysis of expression of tumor-associated epitopes for antibody and human cytotoxic T cell recognition. J Immunother 1993; 14: 127–135
   Web of Science ®Google Scholar
• Acres R B, Hareuveni M, Balloul J M, et al. Vaccinia virus MUC1 immunization of mice: Immune response and protection against the growth of murine tumors bearing the MUC1 antigen. J Immunother 1993; 14: 136–143
   Web of Science ®Google Scholar
• Ding L, Lalani E N, Reddish M, et al. Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: Effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene. Cancer Immunol Immunother 1993; 36: 9–17
   PubMed Web of Science ®Google Scholar
• Rosenberg S A, Packard B S, Aebersold P M, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 1988; 319: 1676–1680
   PubMed Web of Science ®Google Scholar
• Rosenberg S A, Spiess P, Lafreniere R A. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 233: 1318–1321
   PubMed Web of Science ®Google Scholar
• Chang A E, Yoshizawa H, Sakai K, et al. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro. Cancer Res 1993; 53: 1043–1050
   PubMed Web of Science ®Google Scholar
• Schwartzentruber D J, Solomon D, Rosenberg S A, et al. Characterization of lymphocytes infiltrating human breast cancer: Specific immune reactivity detected by measuring cytokine secretion. J Immunother 1992; 12: 1–12
   PubMed Web of Science ®Google Scholar
• Rubbert A, Manger B, Lang N, et al. Functional characterization of tumor-infiltrating lymphocytes, lymph-node lymphocytes and peripheral-blood lymphocytes from patients with breast cancer. Int J Cancer 1991; 49: 25–31
   PubMed Web of Science ®Google Scholar
• Jerome K R, Barnd D L, Bendt K M, et al. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 1991; 51: 2908–2916
   PubMed Web of Science ®Google Scholar
• Disis M L, Calenoff E, McLaughlin G, et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 1994; 54: 16–20
   PubMed Web of Science ®Google Scholar
• Peoples G E, Davey M P, Goedegebuure P S, et al. T cell receptor VübT6 mediate tumor-specific cytotoxicity by tumor-infiltrating lymphocytes in ovarian cancer. J Immunol 1993; 151(15)5472–5480
   PubMedGoogle Scholar
• Peoples G E, Yoshino I, Douville C C, et al. TCR VübT6+ CTL recognize tumor-associated antigens related to HER2/neu expression in HLA-A2+ ovarian cancers. J Immunol 1994; 152: 4993–4999
   PubMed Web of Science ®Google Scholar
• Yoshino I, Peoples G E, Goedegebuure P S, et al. Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer. J Immunol 1994; 152: 2393–2400
   PubMed Web of Science ®Google Scholar
• Peoples G E, Goedegebuure P S, Smith R, et al. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 1995; 92: 432–436
   PubMed Web of Science ®Google Scholar
• Jerome K R, Domenech N, Finn O J. Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA. J Immunol 1993; 151(3)1654–1662
   PubMed Web of Science ®Google Scholar
• Stancovski I, Schindler D G, Waks T, et al. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptor. J Immunol 1993; 151(11)6577–6582
   PubMed Web of Science ®Google Scholar
• Nagler A, Morecki S, Ackerstein A, . Experimental and Clinical Cellular Immunotherapy in Bone Marrow Transplantation, G Morstyn, W P Sheridan, et al, 1995, in press
   Google Scholar